Adocia Targeting Insulin Combos After Ultra-Fast Insulin Deal With Lilly
This article was originally published in The Pink Sheet Daily
Executive Summary
A concentrated insulin formulation and extra clinical data were instrumental in Lilly’s second deal on the use of Adocia’s BioChaperone technology for an ultra-fast-acting insulin, with the latest agreement between the two companies providing funds for Adocia to pursue other insulin research areas.
You may also be interested in...
Looking For The New Lantus: Next-Gen Diabetes Hopefuls Defy Risks
The diabetes market presents competitive, commercial, and regulatory challenges, but its size and breadth spur emerging biotechs to develop an ever-wider range of treatments and technologies.
France's Adocia Completes 2012's First Euro Biotech IPO
French drug delivery company, Adocia, raises $33 million to develop new formulations of therapeutic proteins for wound healing, diabetes
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.